Glecaprevir / 1g

Glecaprevir is a medication used in the treatment of chronic hepatitis C. It is a direct-acting antiviral agent that specifically targets the replication of the hepatitis C virus RNA.

Glecaprevir acts as a protease inhibitor; it targets the NS3/4A protease, an enzyme that the hepatitis C virus needs to replicate. By inhibiting this enzyme, glecaprevir helps to stop the virus from multiplying, which allows the body's immune system to clear the infection.

The combination of glecaprevir and pibrentasvir has been a significant advancement in the treatment of HCV, offering high cure rates across various patient populations, including those with challenging-to-treat genotypes or with compensated cirrhosis. Its development and approval have been part of a broader effort to improve HCV treatment outcomes, reduce the duration of treatment, and simplify therapy to a single daily oral dose, enhancing patient compliance and accessibility to effective therapy.

Articles:

- In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir

Publication Date: 21 December 2017

Teresa I. Ng, Rakesh Tripathi, Thomas Reisch, Liangjun Lu, Timothy Middleton, Todd A. Hopkins, Ron Pithawalla, Michelle Irvin, Tatyana Dekhtyar, Preethi Krishnan, Gretja Schnell, Jill Beyer, Keith F. McDaniel, Jun Ma, Guoqiang Wang, Li-Juan Jiang, Yat Sun Or, Dale Kempf, Tami Pilot-Matias, Christine Collins

https://doi.org/10.1128/aac.01620-17

- Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis

Publication Date: Available online 13 February 2020

Pietro Lampertico, Jose A. Carrión, Michael Curry, Juan Turnes, Markus Cornberg, Francesco Negro, Ashley Brown, Marcello Persico, Nicole Wick, Ariel Porcalla, Andreas Pangerl, Eric Crown, Lois Larsen, Yao Yu, Heiner Wedemeyer

https://doi.org/10.1016/j.jhep.2020.01.025

- Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection

Publication Date: Published online 2021 Jan 18

Xiaoqing Liu and Peng Hu

https://doi.org/10.14218%2FJCTH.2020.00078